An official website of the United States government
Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone
Trial Status: complete
This is a randomized Phase 3 study to determine whether treatment with vaccinia virus
based immunotherapy (Pexa-Vec) followed by sorafenib increases survival compared to
treatment with sorafenib in patients with advanced hepatocellular carcinoma who have not
received prior systemic therapy.
Inclusion Criteria
Histological/cytological diagnosis of primary HCC
Advanced stage HCC (Barcelona Clinic Liver Cancer [BCLC] Stage C or B per American Association for the Study of Liver Disease [AASLD] guidelines)
At least one measurable viable tumor in the liver, ≥1 cm longest diameter (LD), using a dynamic imaging technique (arterial phase of triphasic computerized tomography [CT] scan, or dynamic contrast-enhanced magnetic resonance imaging [MRI]), and injectable under imaging-guidance (CT and/or ultrasound)
Child-Pugh Class A
Performance status 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale
Adequate hematological, hepatic, and renal function:
Additional inclusion criteria exist
Exclusion Criteria
Histological diagnosis of cholangiocarcinoma, hepatocholangiocarcinoma, fibrolamellar carcinoma and hepatoblastoma
Symptomatic cardiovascular disease, including but not limited to significant coronary artery disease (e.g., requiring angioplasty or stenting) or congestive heart failure within the preceding 12 months
Current or past history of cardiovascular disease (e.g.. past history of myocardial infarction, ischemic cardiomyopathy) unless cardiology consultation and clearance has been obtained for study participation
History of moderate or severe ascites, bleeding esophageal varices, hepatic encephalopathy or pleural effusions related to liver insufficiency within 6 months of screening
Bulky disease patients - tumors encompassing >50% of the liver volume and / or inferior vena cava invasion
Known significant immunodeficiency due to underlying illness (e.g., HIV/AIDS) and/or immune-suppressive medication including high-dose corticosteroids
Ongoing severe inflammatory skin condition (as determined by the Investigator) requiring medical treatment
History of severe eczema (as determined by the Investigator) requiring medical treatment
Additional exclusion criteria exist
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT02562755.
Locations matching your search criteria
United States
Illinois
Chicago
University of Chicago Comprehensive Cancer Center
Status: Active
Name Not Available
Kansas
Westwood
University of Kansas Hospital-Westwood Cancer Center
Status: Active
Name Not Available
Texas
Dallas
UT Southwestern/Simmons Cancer Center-Dallas
Status: Active
Name Not Available
This is a multi-center, randomized, open-label, Phase 3 study comparing Pexa Vec followed
by sorafenib versus sorafenib in patients with advanced HCC without prior systemic
therapy.
A total of 459 patients were randomly assigned to 2 treatment arms- 234 patients in the
Pexa-Vec followed by sorafenib treatment group and 225 patients in the sorafenib only